| Quarterly Performance/Technical Report of the National Marrow Donor Program |
05-Nov-2009 |
24 pages |
| Authors:
Michelle Setterholm; NATIONAL MARROW DONOR PROGRAM MINNEAPOLIS MN
|
 | 1. Contingency Prepardness: Collect information from transplant centers, build awareness of the Transplant Center Contingency Planning Committee and educate the transplant community about the critical importance of establishing a nationwide contingency response plan. 2. Rapid Identification of Matched Donors : Increase operational efficiencies that accelerate the search process and increase tient access are key to preparedness in a contingency event. 3. Immunogenetic Studies: Increase understanding of the immunologic factors important ... |
|
| National Marrow Donor Program |
04-Nov-2009 |
19 pages |
| Authors:
Michelle Setterholm; NATIONAL MARROW DONOR PROGRAM MINNEAPOLIS MN
|
| 1. Contingency Preparedness: Collect information from transplant centers, build awareness of the Transplant Center Contingency Planning Committee and educate the transplant community about the critical importance of establishing a nationwide contingency response plan. 2. Rapid Identification of Matched Donors : Increase operational efficiencies that accelerate the search process and increase patient access are key to preparedness in a contingency event. 3. Immunogenetic Studies: Increase understanding of the immunologic factors important ... |
|
| Oxygen and Cell Fate Decisions |
27-May-2009 |
10 pages |
| Authors:
Qun Lin; Yuri Kim; Rodolfo M Alarcon; Zhong Yun; YALE UNIV NEW HAVEN CT SCHOOL OF MEDICINE
|
| Molecular oxygen has been known to play a critical role in a wide range of biological processes including glycolysis, mitochondrial respiration, angiogenesis, pulmonary functions, and cardiovascular activities. An emerging theme has developed in recent years that oxygen has significant impact on embryonic development, maintenance of stem cells, and cellular differentiation or cell fate decisions. Among the notable observations, early embryonic development takes place in a hypoxic microenvironment. Hematopoietic stem cells ... |
|
| Development of Medical Technology for Contingency Response to Marrow Toxic Agents Held January 1, 2009 Through March 31, 2009 |
11-May-2009 |
30 pages |
| Authors:
Michelle Setterholm; NATIONAL MARROW DONOR PROGRAM MINNEAPOLIS MN
|
| 1. Contingency Prepardness: Collect information from transplant centers, build awareness of the Transplant Center Contingency Planning Committee and educate the transplant community about the critical importance of establishing a nationwide contingency response plan. 2. Rapid Identification of Matched Donors : Increase operational efficiencies that accelerate the search process and increase tient access are key to preparedness in a contingency event. 3. Immunogenetic Studies: Increase understanding of the immunologic factors important ... |
|
| The Bone Marrow Stem Cell Origin of Human Breast Cancer Using Transgenic Mouse Models |
Oct-2008 |
13 pages |
| Authors:
Sanford H Barsky; OHIO STATE UNIV RESEARCH FOUNDATION COLUMBUS
|
| There is emerging evidence that transformed stem cells may be the source of human cancers. We felt that transgenic mouse models were ideally suited to examine this question and proposed to conduct marrow transplant experiments to test whether marrow stem cells are the cells of breast cancer origin. Our most significant findings included: 1) the demonstration that stromal cells within the transgenic breast cancers contain significant percentages of tissue macrophages, ... |
|
| Quarterly Performance/Technical Report of the National Marrow Donor Program (Trademark) |
30 APR 2008 |
21 pages |
| Authors:
Michelle Setterholm; NATIONAL MARROW DONOR PROGRAM MINNEAPOLIS MN
|
| 1. Contingency Prepardness: Collect information from transplant centers, build awareness of the Transplant Center Contingency Planning Committee and educate the transplant community about the critical importance of establishing a nationwide contingency response plan. 2. Rapid Identification of Matched Donors : Increase operational efficiencies that accelerate the search process and increase patient access are key to preparedness in a contingency event. 3. Immunogenetic Studies: Increase understanding of the immunologic factors important ... |
|
| Inhibition of Rac GTPases in the Therapy of Chronic Myelogenous Leukemia |
01-Apr-2008 |
77 pages |
| Authors:
CHILDREN'S HOSPITAL MEDICAL CENTER CINCINNATI OH
|
| Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disease (MPD) characterized by the expression of the p210-BCR/ABL fusion gene [1]. This gene is produced by the reciprocal translocation (9; 22) (q34; q11) that juxtaposes the 3 end of Abelson leukemia virus (ABL) gene with the 5 end of the breakpoint cluster region (Bcr) gene on chromosome 22. The transcript formed as a result encodes for the BCR/ABL fusion protein with ... |
|
| Properties of Leukemia Stem Cells in a Novel Model of Cml Progression to Lymphoid Blast Crisis |
01-Oct-2007 |
9 pages |
| Authors:
Craig T Jordan; ROCHESTER UNIV NY
|
| The objective of the study was to employ a novel mouse model of CML blast crisis to characterize various forms of leukemia stem cells (LSC) and their relative properties. In particular, distinguishing how differing normal target cells contribute to disease pathogenesis was regarded as an important priority in establishing relative heterogeneity of LSC. |
|
| Mechanisms of Disease Persistence in Chronic Myelogenous Leukemia |
01-Oct-2007 |
18 pages |
| Authors:
Richard L Defoe; Brian J Druker; OREGON UNIV PORTLAND
|
| Disease persistence is the main issue faced by CML patients on therapy with imatinib and eradication of persistent malignant cells will be critical for the long-term success of kinase inhibitor therapy. Mechanisms underlying acquired resistance to imatinib have been extensively studied and the manner by which mutations of the Bcr-Abl kinase domain can reduce or eliminate sensitivity of CML cells to imatinib has been well characterized. Disease persistence in responding ... |
|
| Cord Blood Stem Cell Procurement in Minority Donors |
MAR 2007 |
10 pages |
| Authors:
Voravit Ratanatharathorn; WAYNE STATE UNIV DETROIT MI
|
| This progress report summarizes the clinical activity of cord blood procurement and the preliminary analysis of the yield of cord blood cells for the purpose of clinical transplantation. The purpose of collection and procurement of cord blood is for public use and will be accessible to all stem cell transplantation centers worldwide. Cord blood is a readily available source of hematopoietic stem cells. It is more accessible than other sources ... |
|
| HLA Typing for Bone Marrow Transplantation |
31 JAN 2007 |
4 pages |
| Authors:
Patricia A. Coppo; Judy W. Davis; Steve M. Spellman; NATIONAL MARROW DONOR PROGRAM MINNEAPOLIS MN
|
| Task 1 : Evaluate optimal short term storage parameters for stimulated and unstimulated leukapheresis (donor lymphocytes) and bone marrow products, including the type of storage media and the cell concentration, in addition to temperature and duration of storage before processing or infusion. Task 2: The NMDP has developed an algorithm that "predicts' high resolution HLA typing results on donor samples that exist in the Registry with only low or intermediate ... |
|
| Engineering Bony Hybrid Organs In Vitro |
NOV 2006 |
35 pages |
| Authors:
D. J. Mooney; P. Krebsbach; J. Linderman; S. Morrison; S. Takayama; C. Y. Wang; HARVARD UNIV CAMBRIDGE MA DIV OF ENGINEERING AND APPLIED SCIENCES
|
| Hybrid bony organs containing mineralized tissue, marrow and microcirculatory compartments could provide extremely novel and life-saving biosensors and tissue replacements. Previous progress in engineering distinct elements of bone suggests this more complex goal is feasible, but the challenges of integrating these elements into a single organ remain to be addressed. We are exploiting recent advances in stem cell biology, materials sciences, and microfabrication to create complex, multi-component bony organs. Materials ... |
|
| Identification of Stem Cells in a Novel Human Mammary Epithelial Culture (HMEC) System that Reproducibly Demonstrates Ductal Organotypic Architecture in 3 Weeks |
OCT 2006 |
55 pages |
| Authors:
Jean J. Latimer; MAGEE WOMENS HEALTH CORP PITTSBURGH PA
|
| Our laboratory has published a novel culture system for Human Mammary Epithelial Cells (HMEC), both normal and malignant. This system allows for unusually long-term (3 months or longer) establishment of normal primary cultures that begin as three-dimensional "mammospheres," which are structures made up of 40-100 epithelial cells. These mammospheres subsequently differentiate into complex organotypic branching ducts and lobules that demonstrate Epithelial Specific Antibody (ESA) staining, lumen, polarized nuclei, desmosomes along ... |
|
| Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis |
OCT 2006 |
9 pages |
| Authors:
Craig T. Jordan; ROCHESTER UNIV NY
|
| Progression of CML from chronic phase to lymphoid blast crisis is a poorly characterized event. However, at least some of the molecular events that accompany evolution of the disease have been described. One such event, mutation of the p16Ink4a/p19Arf locus, is known to occur in approximately 50% of patients developing acute lymphoid disease. Based on this observation, we generated a novel mouse model in which combination of the well-known BCR/ABL ... |
|
| Quarterly Performance/Technical Report of the National Marrow Donor Program |
01 MAY 2006 |
37 pages |
| Authors:
Patrica A. Coppo; Judy W. Davis; Steve M. Spellman; NATIONAL MARROW DONOR PROGRAM MINNEAPOLIS MN
|
| Contract N00014-05-1-0859: 1. Contingency Preparedness: Collect information from transplant centers build awareness of the Transplant Center Contingency Planning Committee and educate the transplant community about the critical importance of establishing a nationwide contingency response plan. 2. Rapid Identification of Matched Donors : Increase operational efficiencies that accelerate the search process and increase patient access are key to preparedness in a contingency event. 3, Immunogenetic Studies: Increase understanding of the immunologic ... |
|
| Identification of Stem Cells in a Novel Human Mammary Epithelial Culture (HMEC) System that Reproducibly Demonstrates Ductal Organotypic Architecture in 3 Weeks |
OCT 2005 |
55 pages |
| Authors:
Jean J. Latimer; MAGEE WOMENS HEALTH CORP PITTSBURGH PA
|
| Our laboratory has published a novel culture system for Human Mammary Epithelial Cells (HMEC), both normal and malignant. This system allows for unusually long-term (3 months or longer) establishment of normal primary cultures that begin as three-dimensional "mammospheres," which are structures made up of 40-100 epithelial cells. These mammospheres subsequently differentiate into complex organotypic branching ducts and lobules that demonstrate Epithelial Specific Antibody (ESA) staining, lumen, polarized nuclei, desmosomes along ... |
|
| Proteinated Subnano Particles of Elemental Selenium for the Treatment of Breast Cancer |
SEP 2005 |
9 pages |
| Authors:
Fritz Sieber; MEDICAL COLL OF WISCONSIN MILWAUKEE
|
| The purpose of this award is to test in preclinical models the hypothesis that cytotoxic conjugates of elemental selenium and proteins are safe and effective for the systemic therapy of invasive breast cancer. The grant has three specific aims, to evaluate the safety and efficacy of systemically administered Se(O)-protein conjugates in athymic nude mice bearing xenografts of human breast cancer cells; to assess the functional integrity of conjugate treated normal ... |
|
| Pathogenic Mechanism of Malignant Progression in Chronic Myelogenous Leukemia |
SEP 2005 |
9 pages |
| Authors:
Jean Y. Wang; CALIFORNIA UNIV SAN DIEGO LA JOLLA
|
| Chronic myelogenous leukemia (CML) is a progressive disease of the hematopoietic stem cell (HSC). It has long been postulated that BCR-ABL causes genomic instability, which then drives the malignant progression of CML. We propose that BCR-ABL causes a chronic instability through a congruence of events that are accidentally combined to place the genome at risk. In particular, we focus on three events: production of reactive oxygen species (ROS), reduction in ... |
|
| Development of a Novel Prognostic Marker to Link a Potential Tumor Suppressor Gene at Chromosome 6q to Aberrant Signal Transduction Pathway in Breast Cancer |
AUG 2005 |
85 pages |
| Authors:
Pan Zheng; OHIO STATE UNIV RESEARCH FOUNDATION COLUMBUS
|
| This is the final report on the grant "Development of a novel diagnostic marker to link a potential tumor suppressor gene at chromosome 6q to aberrant signal transduction pathway in breast cancer." The purpose of the grant proposal is to examine the hypothesis that protein phosphatase laforin is a tumor suppressor in cancers through its function as the specific phosphatase of GSK-3BETA and the loss of function of laforin causes ... |
|
| Mammary Stem Cell Susceptibility to Carcinogenesis |
JUL 2005 |
19 pages |
| Authors:
Sue C. Heffelfinger; CINCINNATI UNIV OH
|
| Mammary tumor formation is thought to be the consequence of transformation of undifferentiated pluripotent stem cells. Little is known about the character of mammary gland stem cells. Examination of mammary gland development has indicated that there may be three distinct types of stem/progenitor cells (S/PC); those which only form ductal structures, those which only form alveolar structures and those which form all mammary gland structures. The goal of this work ... |
|
| Preclinical Mouse Models of Neurofibromatosis |
OCT 2004 |
48 pages |
| Authors:
Kevin M. Shannon; CALIFORNIA UNIV SAN FRANCISCO
|
| This report describes the fourth year of research effort by a Consortium of investigators who are working to develop, characterize and utilize strains of mice that accurately model tumors that develop in persons with NF1 and NF2. This Consortium has made substantial progress toward accomplishing the goal of generating models of NF1 and NF2-associated tumors for biologic and preclinical therapeutic trials and of exploiting these mice to address biologic and ... |
|
| The Origin and Significance of Mammary Intraductal Foam Cells |
SEP 2004 |
6 pages |
| Authors:
Sanford H. Barsky; CALIFORNIA UNIV LOS ANGELES
|
| Intraductal "foam cells" are the most commonly encountered cells in spontaneous nipple discharge, nipple aspirate fluid and ductal lavage yet their origin and significance remain a mystery. They frequently surround DCIS and other intraductal proliferations but their presence has been regarded as a nuisance since they often hide the diagnostically more important epithelial cells. Our previous immunocytochemical studies with macrophage (CD68, lysozyme), epithelial (cytokeratin, estrogen receptor) and myoepithelial (smooth muscle ... |
|
| Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence |
SEP 2004 |
121 pages |
| Authors:
Charles A. Coltman Jr; CANCER THERAPY AND RESEARCH FOUNDATION SAN ANTONIO TX
|
| A serious late complication associated with breast cancer treatment is the increased risk for development of therapy-related hematologic malignancies. The goal of this biologic study is to determine whether dose- intensive adjuvant regimens for breast cancer induce genetic damage to hematopoietic stem cells, defined by the emergence of clonal hematopoiesis. Clonal hematopoiesis has been proposed as an early marker of. hematopoietic stem cell damage, preceding the acquisition of critical, recurring ... |
|
| Randomized Trial of Interleukin-2 (IL-2) as Early Consolidation Following Marrow Ablative Therapy with Stem Cell Rescue for Metastatic Breast Cancer |
OCT 2003 |
12 pages |
| Authors:
Wolfram E. Samlowski; UTAH UNIV SALT LAKE CITY
|
| Interleukin-2 (IL-2) has the capacity to activate lymphocytes to kill multidrug resistant cancer cells. Our phase I data established the feasibility of administering a single course of low-dose IL-2 (1.6 million IU/m2/day as a continuous i.v. infusion for 18 days) as consolidation treatment to patients with metastatic breast cancer early after intensive chemotherapy. Seven patients (60%) remained in complete remission at a median of >435 days post stem cell transplantation. ... |
|
| A Novel Strategy to Inhibit Osteolytic Bone Metastases of Breast Cancer |
MAY 2002 |
10 pages |
| Authors:
Joanne T. Douglas; ALABAMA UNIV IN BIRMINGHAM
|
| More than 70% of women who die from breast cancer show osteolytic bone metastases which cause significant morbidity. Therefore, inhibition of osteolytic bone metastasis would improve the quality of life of patients with advanced breast cancer. Rational therapies to prevent osteolytic bone metastasis of breast cancer should be based on the unique characteristics of the bone microenvironment. The development and progression of osteolytic bone metastases are dependent on the resorption ... |
|
| Ex vivo Expanded Megakaryocytes for Supportive Care of Breast Cancer Patients |
OCT 2001 |
39 pages |
| Authors:
Isaac Cohen; Jane N. Winter; NORTHWESTERN UNIV EVANSTON IL
|
| The main goal of our project is to culture human hematopoietic stem cells to produce enough megakaryocytes (MK) to be transfused to patients as a supplement to the conventional stem cell transplant. The transfused megakaryocytes will generate platelets, eliminating the need for repeated platelet transfusions post-transplant. Growth factors (GF) are needed to grow and expand MK using an ex vivo expansion protocol. We planned, as described in our original proposal, ... |
|
| Late Hematologic Complications of Mustard Gas |
SEP 2001 |
5 pages |
| Authors:
Mostafa Ghanei; BAGHIATALLAH UNIV OF MEDICAL SCIENCES TEHRAN (IRAN)
|
| Chemical warfare agents in general and mustard gas in particular were used by Iraq against Iranian combatants during the Iraq - Iran war from 1981 to 1988. Mustard affects many organs such as the skin, eyes, and lungs, as well as the gastrointestinal, endocrine, and hematopoietic system. Although some of these complications are transient or treatable in the early phases, late complications may remain for years. Alkylating effects of mustard ... |
|
| The HLA Dictionary 2001: A Summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 Alleles and Their Association with Serologically Defined HLA-A, -B, -C, -DR and -DQ Antigens |
AUG 2001 |
|
| Authors:
G. M. Schreuder; C. K. Hurley; S. G. Marsh; M. Lau; M. Maiers; NATIONAL INSTITUTES OF HEALTH BETHESDA MD
|
 | This report presents the serologic equivalents of 123 HLA-A 272 HLA-B and 155 HLA-DRBl alleles. The equivalents cover over 64% of the presently identified HLA-A -B and -DRBl alleles. The dictionary is an update of the one published in 1999 and also includes equivalents for HLA-C DRB3 DRB4 DFB5 and DQB 1 alleles. The data summarize information obtained by the WHO Nomenclature Committee for Factors of the HLA System the ... |
|
| The Role of Mammary Epithelial Stem Cells in the Transition from Normal to Malignant Epithelium |
MAY 2001 |
44 pages |
| Authors:
Robert B. Dickson; GEORGETOWN UNIV WASHINGTON DC MEDICAL CENTER
|
| A steadily growing body of evidence indicates that mouse and human mammary cancers present as clonal diseases that depend upon genetic alterations both for their initiation and progression. It is considered likely, but not proven, that the only cells of any tissue able to pass on genetic aberrations to their progeny are those that retain the capacity for cell division and that do not become terminally differentiated. This hypothesis has ... |
|
| Retroviral Transfer of Human Mutated Thymidylate Synthase Gene into Hematopoietic Stem Cells for Protection from High-Dose Fluoropyrimidine Toxicity |
OCT 2000 |
9 pages |
| Authors:
Naoko Takebe; Robert Gallo; MARYLAND UNIV BALTIMORE
|
| In the field of breast cancer, the significant cytoreduction followed by consolidation chemotherapy has been accepted to reduce disease relapse in breast cancer. However, myelosuppression still impose restrictions on the optimization of this treatment modality. Insertion of drug resistance genes into hematopoietic progenitor cells offers an additional approach to allow further dose intensification and treatment post transplant. We have generated and characterized human thymidylate synthase (TS) mutants, one of which ... |
|
| Office of Naval Research Cooperative Agreement Number N00014-96-2-0016 |
10 FEB 2000 |
54 pages |
| Authors:
Patricia A. Coppo; Dennis Confer; Robert Pinderhughes; R. D. Brown; Janet Hegland; NATIONAL MARROW DONOR PROGRAM MINNEAPOLIS MN
|
| The objectives of activities conducted through this cooperative agreement were to: increase the availability of hematopoietic stem cell transplantation; improve scientific understanding of factors leading to successful post-transplant outcomes; and develop and test centralized contingency responses for the treatment of military and/or civilian casualties exposed to nuclear or biological marrow toxic agents. These objectives were successfully met through the following activities. The transition ... |
|
| Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence |
SEP 1999 |
79 pages |
| Authors:
Charles A. Coltman Jr.; CANCER THERAPY AND RESEARCH FOUNDATION SAN ANTONIO TX
|
| The goal of this study is to determine whether dose-intensive adjuvant regimens for breast cancer induce genetic damage to hematopoietic stem cells, defined by the emergence of clonal hematopoiesis. Two different assays are used to detect clonality: the HUMARA (human androgen receptor) assay to estimate the incidence of early genetic damage defined by the presence of clonal hematopoiesis and microsatellite instability testing to screen for loss ... |
|
| UCLA/USC Tumor Tissue Bank |
OCT 1998 |
18 pages |
| Authors:
Dennis J. Slamon; CALIFORNIA UNIV LOS ANGELES
|
| The UCLA/USC Tissue Bank was established to provide research investigators with a ready source of human tissue samples for basic and clinical research projects directed at a greater understanding of various aspects of human breast cancer. The bank has been successful at accruing some 8328 tissue samples to all of the subcomponent banks comprising the main bank. Of these tissues, 2478 are breast cancer specimens while ... |
|
| Splicing Variants of Estrogen Receptor in Breast Cancer |
OCT 1998 |
65 pages |
| Authors:
Richard J. Miksicek; STATE UNIV OF NEW YORK AT STONY BROOK RESEARCH FOUNDATION
|
| Progress reported for year 4 of this award includes: (1) an analysis of ER-alpha mRNA variants in two cell lines (TG-1 and TG-3c) from the MCF10AT series (a model for preneoplastic breast disease), (2) PCR analysis of ER-alpha mRNA in M13 SV1 and R(sub 2)N(sub 1) cells (SV40 immortalized normal human breast epithelial lines developed as a model for breast stem cells), and (3) continued characterization of selected ER-alpha splicing ... |
|
| Transgenic Rat Models for Breast Cancer Research |
OCT 1998 |
|
| Authors:
Anne E. Griep; WISCONSIN UNIV-MADISON
|
| The laboratory rat is an important model for studying breast cancer due to the similarities in this disease between rats and humans. However, limited knowledge in manipulating the rat genome through transgenesis has prevented researchers from answering important questions in breast cancer research. We proposed to carry out detailed studies to optimize the variables in transgenic manipulation, to extend transgenic rat technology to inbred rat strains, and to develop rat ... |
|
| Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence |
SEP 1998 |
31 pages |
| Authors:
Charles A. Coltman; CANCER THERAPY AND RESEARCH FOUNDATION SAN ANTONIO TX
|
| Dose intensive anthracycline-based adjuvant regimens improve disease-free survival in breast cancer patients; however, recent studies also show an increased risk for development of therapy-related hematologic malignancies. Models of leukemogenesis propose that clonal hematopoiesis may be an early marker of genetic damage, preceding the acquisition of critical, recurring genetic alterations associated with the development of therapy related myelodysplastic syndromes and acute leukemia. The goal of this study is to determine whether ... |
|
| Inhibition of Stem Cell Mobilization in Breast Cancer Patients by a Circulating Factor |
SEP 1998 |
32 pages |
| Authors:
John G. Sharp; NEBRASKA UNIV AT OMAHA
|
| Preliminary data indicated some breast cancer patients who are candidates for high dose therapy requiring prior collection of a cytokine- mobilized blood stem cell harvest for reinfusion to restore hematopoiesis, respond poorly to mobilization. This makes collection of an adequate harvest inconvenient, prolonged and costly. Poor mobilizers appear to have a circulating inhibitor of mobilization which can be assayed in a mouse model. When injected before cytokine administration mobilization is ... |
|
| Potential Role of the Tumor Suppressor ADENOMATOUS POLYPOSIS COLT in Polarization of Breast Epithelial Cells |
AUG 1998 |
25 pages |
| Authors:
Kristi Neufield; UTAH UNIV SALT LAKE CITY
|
| Recent evidence suggests that the adenomatous polyposis coli (APC) gene participates in breast tumorigenesis. Although a precise biological function for APC protein has not yet been determined, it has been shown that the APC protein interacts with beta-catenin and plakoglobin in vivo. Beta-catenin and plakoglobin are components of two specialized anchoring junctions, the adherens junction, a site of attachment for bundles of actin filaments, and the desmosome, a site of ... |
|
| UCLA/USC Tumor Tissue Bank |
OCT 1997 |
17 pages |
| Authors:
Dennis J. Slamon; CALIFORNIA UNIV LOS ANGELES
|
| The UCLA/USC Tissue Bank was established to provide research investigators with a ready source of human tissue samples for basic and clinical research projects directed at a greater understanding of various aspects of human breast cancer. The bank has been successful at accruing some 2968 tissue samples to 5 of the 6 subcomponent banks comprising the main bank. Of these tissues, 799 are breast cancer specimens ... |
|
| Gene Therapy of Breast Cancer: Studies of Selective Promoter/Enhancer- Modified Vectors to Deliver Suicide Genes |
SEP 1997 |
24 pages |
| Authors:
Donald W. Kufe; DANA-FARBER CANCER INST BOSTON MA
|
| The overall goal of this project is to develop gene therapy strategies for breast cancer by translation of studies derived from the DF3/MUCl gene. We have completed Tasks 1 and 2 as outlined in the Statement of Work using the DF3 promoter to selectively drive transgenes in breast cancer cells. The DF3 promoter has been used in an adenoviral vector to selectively detect and eliminate breast cancer cells that contaminate ... |
|
| C-KIT AND Stem Cell Factor Expression in Breast Cancer |
SEP 97 |
23 pages |
| Authors:
Susan Hines; VIRGINIA COMMONWEALTH UNIV RICHMOND
|
| We have proceeded to investigate some of the biologic consequences of c-kit and SCF coexpression since simple coexpression of receptor and ligand may imply, but does not prove, a potential autocrine(or paracrine) loop. We have therefore, constructed an autocrine loop by transfecting the breast cancer cell line, MCF7, that only expresses SCF, with a c-kit expression vector (21). MCF7 cells were transfected with both the c-kit expression vector and the ... |
|
| The Potential Role of Calcitriol Analogs in the Management of Breast Cancer |
OCT 96 |
21 pages |
| Authors:
Daniel D. Bikle; CALIFORNIA UNIV SAN FRANCISCO
|
| Breast cancer is the second leading cause of cancer deaths among females and a leading cause of death of all middle age women in the United States. Epidemiologic evidence suggests a role for vitamin D deficiency in the development of breast cancer. Moreover, vitamin D receptors have been found in most breast cancers, and their presence appears to be a favorable prognostic sign. While much clinical focus has been given ... |
|
| Megakaryocytopoiesis in Stem Cell Transplantation |
OCT 96 |
26 pages |
| Authors:
Isaac Cohen; NORTHWESTERN UNIV EVANSTON IL
|
| The overall objective of this research proposal is to improve the capacity of stem cells to engraft the megakaryocytic lineage. Ex vivo expansion of bone marrow megakaryocyte progenitors in the presence of thrombopoietin (TPO) was significantly enhanced by a soluble factor present in cultures of confluent marrow stromal cells. We are presently attempting to identify this factor. Addition of interleukin-3, but not stem cell factor, to TPO, enhances the expansion ... |
|
| Gene Therapy of Breast Cancer: Studies of Selection Promoter/Enhancer- Modified Vectors to Deliver Suicide Genes |
SEP 1996 |
41 pages |
| Authors:
Donald W. Kufe; DANA-FARBER CANCER INST BOSTON MA
|
| Tumor contamination of bone marrow (BM) and peripheral blood (PB) may affect the outcome of patients receiving high dose chemotherapy with autologous transplantation of hematopoietic stem cell products. We demonstrate that replication defective adenoviral vectors containing DF3/MUC1 carcinoma-selective promoter can be used to selectively transduce contaminating carcinoma cells. Adenoviral-mediated reporter gene expression in breast cancer cells was 5-6 orders of magnitude higher than that found in BM, PB and CD34+ ... |
|
| Alternative Splicing in Normal Development and in Breast Cancer |
JUL 96 |
20 pages |
| Authors:
John R. Bermingham; CALIFORNIA UNIV SAN DIEGO LA JOLLA
|
| Alterations in the splicing patterns of key regulatory genes are likely to play an important role in oncogenesis. The ASF/SF2 protein is one of a family of SR splicing factors that have been shown to regulate splice site choice in vitro. We have mapped the ASF/SF2 gene to 17q21.3-q22 in humans, and close to the Ovum mutant locus on chromosome 11 in mice. Our current objective is to examine the ... |
|
| Environmental Risk Assessments Based on Bone Marrow Cell Kinetic |
01 FEB 96 |
131 pages |
| Authors:
Troyce D. Jones; Max D. Morris; Jafar S. Hasan; OAK RIDGE NATIONAL LAB TN
|
| Risk of acute mortality from ionizing radiations, leukemia, and cancer are modeled for exposures to X-rays, photons, fission-produced neutrons, and neutrons produced by thermonuclear processes. Risks from protracted exposures are evaluated in terms of sublethal injury to cells, repair of sublethal injury, I-hit cell killing, killing of cells having unrepaired sublethal injury, and radiation-induced cellular repopulation. These cellular effects can be used to equate the protracted exposure to a prompt ... |
|
| Molecular Detection of Breast Cancer |
FEB 96 |
34 pages |
| Authors:
Michael F. Clarke; MICHIGAN UNIV ANN ARBOR
|
| Breast cancer is the second leading cause of cancer death among American women, with over 170,000 new cases and 50,000 deaths each year. Despite advances in detection and treatment, mortality from these diseases remains high. Traditional modes of treatment including radiation therapy, chemotherapy, and hormonal therapy have been useful, but are limited by the emergence of treatment-resistant cancer cells. Clearly new approaches are needed to treat these diseases. This project ... |
|
| Iron Deprivation Treatment of Breast Cancer: Pre-Clinical Studies |
JAN 96 |
14 pages |
| Authors:
John D. Kemp; IOWA UNIV IOWA CITY
|
| Progress has been made toward the first four of the five tasks listed in the statement of work. The most interesting results have come in pursuit in tasks one and two. We have discovered (and published) the fact that the breast cancer cell lines SK-BR-3 and MDA-MB-231 vary with respect to their sensitivity to iron deprivation treatment. Sensitivity to monoclonal anti-transferrin receptor antibodies appears to be correlated with the relative ... |
|
| UCLA/USC Tumor Tissue Bank |
OCT 95 |
12 pages |
| Authors:
Dennis J. Slamon; CALIFORNIA UNIV LOS ANGELES
|
| The UCLA/USC Tissue Bank was established to provide research investigators with a ready source of human tissue samples for basic and clinical research projects directed at a greater understanding of various aspects of human breast cancer. The bank has been successful at accruing some 1020 tissue samples to 5 of the 6 subcomponent banks comprising the main bank. Of these tissues, 371 are breast cancer specimens while the remaining represent ... |
|
| Megakaryocytopoiesis in Stem Cell Transplantation |
20 SEP 95 |
13 pages |
| Authors:
Isaac Cohen; NORTHWESTERN UNIV EVANSTON IL
|
| Following high-dose chemotherapy for the treatment of malignant disease, reinfusion of peripheral blood stem cells collected during treatment with growth factors usually results in delayed platelet engrafiment as compared to neutrophil recovery. The overall objective of this research proposal is to improve the capacity of stem cells to engrafi ;the megakaryocytic lineage. To achieve this goal we carried out ex vivo expansion of megakaryocyte (Mk) progenitors from human bone marrow ... |
|
Reports by Keyword(s)
HEMATOPOIETIC CELLS
